Danaher announces leadership appointment

Danaher Corporation (NYSE: DHR) announced today that effective January 1, 2021 its Board of Directors has appointed Jennifer L. Honeycutt to the position of Executive Vice President of Danaher Corporation, with responsibility for the Company's Beckman Coulter Life Sciences, Integrated DNA Technologies (IDT), Leica Microsystems, Molecular Devices, Pall, Phenomenex, and SCIEX businesses. With this appointment, Ms. Honeycutt will become an executive officer of the Company.

Prior to this appointment, Ms. Honeycutt, 51 years old, was a Vice President and Group Executive overseeing Pall, IDT, and the Danaher Life Sciences platform in China , and served as President of Pall. She previously served as President of Beckman Coulter Life Sciences from 2013 to 2016 and is also a longstanding member of Danaher's Diversity + Inclusion Council.

In her new role, Ms. Honeycutt will continue to report directly to Rainer M. Blair , President and Chief Executive Officer.

Mr. Blair stated, "Jennifer's leadership has been an integral driver of the growth and success of Pall and our Life Sciences platform over the past several years. The combination of Jennifer's strong operational track record, innovative mindset and commitment to the Danaher Business System has enabled her to make a tremendous impact. Jennifer's twenty-year Danaher career exemplifies our Shared Purpose – Helping Realize Life's Potential – and we look forward to her continued successes and contributions in the years to come."

Ms. Honeycutt joined Danaher in 1999 via the acquisition of Hach and subsequently served in a series of progressively more responsible general management roles within Hach Ultra Analytics, Anderson Instrument Company and Linx Printing Technologies. Ms. Honeycutt started her career at Hach in 1991 as a research chemist. She earned B.A. degrees in Chemistry and French from Grinnell College and an MBA in Technology Management from the University of Denver .

ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of more than 67,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential . For more information, please visit www.danaher.com .

Cision View original content: https://www.prnewswire.com/news-releases/danaher-announces-leadership-appointment-301191639.html

SOURCE Danaher Corporation

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Seegnal (TSXV:SEGN)

Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults -- a significant clinical and financial challenge... Keep Reading...
Cardiologist wearing virtual reality glasses.

Top 3 Medical Device ETFs for Investors in 2026

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or... Keep Reading...
Stethoscope connected to a phone with medical data overlay.

Top 3 Small-cap Medical Device Stocks (Updated January 2026)

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).Wearable medical devices and the use of artificial intelligence in medical... Keep Reading...
Scientists working in a modern medical research laboratory.

Pathways to Commercialising Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and... Keep Reading...
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians. BlinkLab states in its Wednesday (March 12) release that the study is the largest digital... Keep Reading...

Interactive Chart

Latest Press Releases

Related News